India sees approximately 1.4 million new cancer cases annually — making it one of the largest oncology markets in the world. More importantly, the combination of scale, genetic diversity, and a rapidly digitizing health system creates conditions unlike anywhere else.
The Genomic Advantage
Indian populations carry genetic variants that are dramatically underrepresented in global clinical datasets. This is both a challenge and an extraordinary scientific opportunity.
Precision oncology built on Indian genomic data is not just a local market play. It is globally differentiated science.
Companies like 4baseCare are building proprietary genomic databases from clinical outcomes that global competitors simply cannot replicate. The moat is scientific and regulatory — not commercial.
The Investment Thesis
We believe the next 5 years will see 3–5 Indian genomics companies emerge with the potential for global-scale impact. Our thesis focuses on companies with: (1) proprietary datasets, (2) regulatory-path clarity, and (3) founders with both scientific and clinical credibility.
The window to build India-first, globally-differentiated life sciences companies is open right now. We intend to back the founders who understand that.